ATLANTA – December 9, 2010 – GeoVax Labs, Inc.
(OTCQB/OTCBB: GOVX) (the “Company”), announced today
that early results from part A of an ongoing phase 2a clinical
trial indicate an excellent safety profile and highly reproducible
immunogenicity. The phase 2a trial is testing two recombinant
DNA-vectored vaccine inoculations; the first at week 0 and the
second at week 8, followed by two recombinant MVA-vectored vaccine
inoculations, at weeks 16 and 24. The still-blinded data for 180
trial participants, enrolled at a ratio of two vaccine recipients
for each placebo, reveal no safety concerns. These results are very
similar to those observed in the Phase 1 trial. The trial,
designated HVTN 205, is being conducted by the HIV Vaccine Trials
Network (HVTN), which is funded by the National Institute of
Allergy and Infectious Diseases (NIAID), part of the U.S. National
Institutes of Health.

Of particular interest are assay results measuring
vaccine-induced cellular (T-cell) immune responses, which are
available for 128 of the participants. These tests revealed
cellular immune response rates similar to those observed in the
Phase 1 trial. Additional testing is ongoing to measure antibody
responses and to further characterize cellular immune responses.
Data will continue to be accumulated as the trial is completed.

“The high level of safety was expected” said Dr.
Harriet Robinson, Chief Scientific Officer of GeoVax,
“because of the excellent tolerability of recombinant DNA and
recombinant MVA vaccine vectors in humans in our, as well as other
prior trials. The apparent reproducibility of vaccine
immunogenicity is very encouraging. The immunogenicity data not
only indicate that our vaccine products are functioning as designed
but also demonstrate the capabilities of the central HVTN
laboratory whose scientists have developed and validated the assays
that are so critical to clinical vaccine testing.” About
GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for
diseases caused by HIV (Human Immunodeficiency Virus – that
leads to AIDS). Our goals include developing HIV/AIDS vaccines for
global markets, overseeing the manufacture and testing these
vaccines under GMP/GLP conditions (FDA guidelines), conducting
clinical trials for vaccine safety and effectiveness, and obtaining
regulatory approvals to move the product forward. All preventative
Phase 1 human clinical trials conducted to date were designed to
test combinations and dose levels of our DNA and MVA vectored
vaccines, their ability to raise anti-HIV humoral (antibody) and
cellular (CD4+ helper and CD8+ cytotoxic T cell) immune responses,
as well as, the vaccines’ safety. Successful results from
Phase 1 testing supported the initiation of the first Phase 2
testing. GeoVax's Phase 2 human trial began in January 2009 and
will ultimately involve 300 participants at sites in the United
States and South America. Recently GeoVax began enrolling patients
in a Phase 1 therapeutic trial for individuals already infected
with HIV. For more information, please visit www.geovax.com.

### Forward-Looking Statements Certain statements in this
document are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act These statements are based
on management's current expectations and are subject to uncertainty
and changes in circumstances. Actual results may differ materially
from those included in these statements due to a variety of
factors, including whether: GeoVax can develop and manufacture its
vaccines with the desired characteristics in a timely manner,
GeoVax's vaccines will be safe for human use, GeoVax's vaccines
will effectively prevent AIDS in humans, vaccines will receive
regulatory approvals necessary to be licensed and marketed, GeoVax
raises required capital to complete vaccine development, there is
development of competitive products that may be more effective or
easier to use than GeoVax's products, GeoVax will be able to enter
into favorable manufacturing and distribution agreements, and other
factors, over which GeoVax has no control. GeoVax assumes no
obligation to update these forward-looking statements, and does not
intend to do so. More information about these factors is contained
in GeoVax's filings with the Securities and Exchange Commission
including those set forth at "Risk Factors" in GeoVax's Form
10-K.